Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex Benefits And Broad-Spectrum Efficacy In Treatment-Resistant Epilepsies At AES 2024 Annual Meeting
Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex Benefits And Broad-Spectrum Efficacy In Treatment-Resistant Epilepsies At AES 2024 Annual Meeting
DUBLIN, Dec. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced nine company-sponsored Epidiolex (cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California.Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms
將要展示的九篇摘要的數據，包括來自EpiCom試驗的首次數據，這是對患有結節性硬化綜合徵的患者的行爲結果進行的前瞻性評估，顯示行爲症狀嚴重程度有改善。
Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex) surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex caregivers
來自BECOME（Epidiolex的行爲、認知及更多）調查的真實世界數據，顯示長期護理機構護士和結節性硬化綜合徵看護者報告的結果。
For U.S. media and investors only
僅適用於美國媒體和投資者
DUBLIN, Dec. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced nine company-sponsored Epidiolex (cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California.
都柏林，2024年12月6日 /PRNewswire/ -- Jazz Pharmaceuticals plc（納斯達克：JAZZ）今天宣佈九個公司贊助的Epidiolex（大麻二酚）海報將在2024年美國癲癇學會（AES）年會上展示，會議將於12月6日至10日在加利福尼亞州洛杉磯舉行。
Data presented at the meeting includes updated analyses of real-world data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, which characterizes and quantifies seizure and non-seizure outcomes in patients with epilepsy and tuberous sclerosis complex (TSC) treated with Epidiolex. An additional presentation showcases data from the BECOME-LTC survey, which evaluated the perspectives of nurses who care for patients with epilepsy in long-term care (LTC) facilities and group homes, reporting improvements in seizure frequency and in certain non-seizure outcomes associated with Epidiolex treatment. Further, the first presentation of data from the EpiCom trial, a prospective, interventional trial evaluating the impact of adjunctive Epidiolex on TSC-associated neuropsychiatric disorders (TAND), revealed improvements in behavioral symptom severity following treatment initiation.
會議上展示的數據包括來自BECOME-TSC（Epidiolex的行爲、認知及更多）看護者調查的真實世界數據的更新分析，該調查描述並量化了接受Epidiolex治療的癲癇和結節性硬化綜合徵（TSC）患者的發作和非發作結果。另一個展示展示了來自BECOME-LTC調查的數據，該調查評估了在長期護理（LTC）機構和團體家庭中照顧癲癇患者的護士的看法，報告稱與Epidiolex治療相關的發作頻率和某些非發作結果有所改善。此外，EpiCom試驗的首次數據展示，EpiCom是對TSC相關神經精神病（TAND）評估輔助手段Epidiolex影響的前瞻性干預試驗，顯示治療開始後行爲症狀的嚴重程度有所改善。